[Remote] Head of Program Management at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

15+ years of experience in biotech/pharma
At least 7 years in program or portfolio management leadership roles
Advanced Degree highly preferred (PhD, MBA, or MS in Business or Scientific discipline)
Proven track record of building and scaling PMO functions in high-growth environments
Deep understanding of drug development lifecycle from discovery through commercialization
Strong leadership, communication, and stakeholder management skills
Experience with project management tools and systems (e.g., Smartsheet, MS Project)

Responsibilities

Build and Lead PMO: Design and implement a centralized Program Management Office to support all development programs and corporate initiatives
Program Oversight: Provide strategic oversight and hands-on leadership for key programs across discovery, preclinical, clinical, regulatory, and commercial functions
Integration & Alignment: Integrate existing program management practices across departments into a unified framework with standardized tools, processes, and governance
Portfolio Management: Develop and maintain portfolio dashboards, KPIs, and reporting mechanisms for executive leadership and board-level visibility
Cross-Functional Leadership: Partner with R&D, Clinical, Regulatory, Finance, and Operations to ensure program milestones are met and risks are proactively managed
Strategic Planning: Support long-range planning and scenario modeling to inform investment decisions and resource allocation
Team Development: Recruit, mentor, and develop a high-performing program management team

Skills

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free